Since 2014, we’ve monitored, analyzed and classified new CRISPR patent publications worldwide in a dedicated patent database in order to give an overall, independent overview of the IP situation. This unique work and expertise has been quoted by Nature, The Scientist, Bloomberg, Fortune and Quartz among others.
Learn more on our latest CRISPR patent analytics services and patent landscape here.